ArticleTherapeutic advances in medical oncology2026
Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR-mutant NSCLC in the US and China.
Yihong Guo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.